Is pT0 a Reliable End Point for Biomarker Discovery for Preoperative Chemotherapy Response in Patients With Bladder Cancer?
Anil K. Sood(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Justin T. Matulay(Levine Cancer Institute), Vikram M. Narayan(Emory University), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Hui Yao(The University of Texas MD Anderson Cancer Center), Amy Lim(The University of Texas MD Anderson Cancer Center), I-Ling Lee(The University of Texas MD Anderson Cancer Center), Mohammed Seif(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Monitoring dopants by Raman scattering in an electrochemically top-gated graphene transistor
|Nature Nanotechnology|2008|3.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Paraneoplastic Thrombocytosis in Ovarian Cancer
|New England Journal of Medicine|2012|822